November 2010.  The Case for a Marketing Code of Practice  The Marketing Code of Practice Journey  The Parts to the Code  So What?  Examples & Scenarios.

Slides:



Advertisements
Similar presentations
London Medicines Information Service (Northwick Park Hospital) - June 2008 Drug Promotion: The Pharmaceutical Representative. Making the most of Promotional.
Advertisements

FUNCTION OF MEDICAL COUNCIL AND ITS IMPORTANCE IN PPP PROMOTION H.E. Professor Thir Kruy, Secretary of State, MoH President of MCC Intercontinental Hotel.
Continuing Professional Development Conflict of Interest This presentation has been developed by the COI Working Group to assist in the implementation.
Spanish Code of Practice for the Promotion of Medicines CONFIDENTIAL "International congresses, including booth materials and panels, controls related.
Steve Speller. Substances that have the potential to:- do good do harm.
1 STRATEGIC HEALTH PLAN AND ANTICIPATED CHANGES TO MRA/MCC Dr Joey Gouws Director: Inspectorate and Law Enforcement Medicines Regulatory Authority (MRA)
SFEE Disclosure Code October Interactions between the pharmaceutical industry and health care professionals have a profound and positive influence.
Objectives Why we need DHCPL Situations that call for a DHCPL Definitions DHCPL itself–content, presentation, process Target audience Current and future.
Access to Medicine Index 3 rd International Conference for Improving the Use of Medicines Poster 599 Tuesday 15 th November 2011.
Data Protection Paul Veysey & Bethan Walsh. Introduction Data Protection is about protecting people by responsibly managing their data in ways they expect.
Consumer Code for Home Builders Noel Hunter Chairman 1.
Whilst the pharmaceutical industry plays a key role in developing and producing medicines, there is a tension between industry’s need to expand product.
SA Code of Practice for the Marketing of Health Products Marketing Ethics and what does this mean for an HCP? Dr Haseena Gani Executive Officer Sept 2013.
Regulations Relating to Foodstuffs for Infants and Young Children (Foodstuffs, Cosmetics and Disinfectants Act, 1972) Briefing to the Portfolio Committee.
“Worldwide Review of the Profession” Competition & Regulatory Developments ALAN HUNTER.
Voluntary Codes MassMEDIC Meeting Are You Ready to Comply with Massachusetts’ New Pharmaceutical and Medical Device Code of Conduct Law? Linda D. Bentley,
Joint comment by The Nutrition Society of South Africa Association for Dietetics in South Africa Presented by Prof Johann Jerling Medicines and Related.
Organization and Implementation of a National Regulatory Program for the Control of Radiation Sources Enforcement.
Local Assessment of Code of Conduct Complaints. 2 Background  On 08 May 2008 – the local assessment of Code of Conduct complaints was implemented due.
SALDA Presentation to the Honourable Portfolio Committee on Health National Health Act Amendment Bill B March 2012.
© Securities Commission, Malaysia 1 What the Audit Oversight Board will do ICAA-MICPA Audit Forum 3 August 2010.
Complaints and Monitoring (s.9 and 10) Malika Ladha PAAB Reviewer.
Advanced Program in Auditing and Accounting Regulation Module 12 Enhancing Statutory Audit Quality from a Financial Regulator’s Perspective Presenter:
SAHPRA proposals Nov 2009 A GLIMPSE OF WHAT SAHPRA IS INTENDED TO BECOME KEY PROPOSALS FOR SAHPRA NOVEMBER 2009 DR NICHOLAS CRISP.
Code of Conduct Complaints Local Assessment Framework (08 May 2008 – 30 June 2009)
Certificate for Introduction to Securities & Investment (Cert.ISI) Unit 1 Lesson 59:  Breaches, complaints and compensation  The difference between a.
Policy track summary ICIUM 2011 – 18 Nov Policy track topics 1.The pharmaceutical policy process 2.Quality and safety of medicines in LMIC 3.Policy.
Codes of Conduct The International Pharmaceutical Regulatory & Compliance Congress and Best Practice Forum 6 June 2007 Heather Simmonds Director Prescription.
The Pharmaceutical Industry and International Clinical Research: One Company’s Approach Michael Clayman, M.D. Vice President, Lilly Research Laboratories.
1 Harvard University Cambridge, MA March 29, 2007 Medical Device Congress AdvaMed’s Efforts to Promote Compliance Christopher L. White, Esq. Executive.
IPASA presentation to Portfolio Committee on Health 31 October 2014 Abeda Williams.
Medicines and Related Substances Amendment Bill 2008 Presented by: Abeda Williams 5 August 2008 Pharmaceutical Industry Association of South Africa.
Local Assessment of Code of Conduct Complaints. Background  On 08 May 2008 – the local assessment of Code of Conduct complaints was implemented due to.
TOURISM BILL “ THE CONTENTS ” Friday; 17 May 2013.
Medicines and Related Substances Amendment Bill 2008 Pharmaceutical Task Group: Industry Marketing Code Steering Committee Presented by: Maureen Kirkman.
Biotechnology / Life Sciences Ensuring Access Christina Sampogna July 2005 CASRIP – University of Washington, Seattle *Views expressed are those of the.
Portfolio Committee for Health Medicines and Related Substances Amendment Bill (06/08/08) IMSA represents Research Based Pharmaceutical Companies.
PRESENTATION TO THE PORTFOLIO COMMITTEE ON TRADE AND INDUSTRY COMPANIES BILL [B ] 13 August 2008 By: Bernard Peter Agulhas – Acting Chief Executive.
31 October The African Policing Civilian Oversight Forum (APCOF) is a network of state and civil society African practitioners active in policing.
ERIC REURTS Draft SA Marketing Code. Marketing Code Steering Committee PIASA - Pharmaceutical Industry Association NAPM – National Association of Pharmaceutical.
VICH General Principles and current update of VICH Outreach Forum activity 1.
1 CHALLENGES IN REGULATING QUALITY AND RATIONAL USE OF ANTIBIOTICS ALLIANCE FOR THE PRUDENT USE OF ANTIBIOTICS: INAGURAL MEETING COURTYARD.
F Designed to give you knowledge and application of: Section A: Business organisational structure, governance & management A1. The business organisation.
0 Case Study #1 Global Ophthalmology. ACADEMY OF OPHTHALMOLOGY Disclosure  The speaker has no financial interest in the subject matter.
Building community trust and protecting public safety: the Australian national registration of Chinese medicine practitioners Prof Charlie Xue Chair, Chinese.
Medical Device Compliance Congress: Global Device Codes Roundtable - Australia Anne Trimmer.
ETHICAL ISSUES IN HEALTH AND NURSING PRACTICE CODE OF ETHICS, STANDARDS OF CONDUCT, PERFORMANCE AND ETHICS FOR NURSES AND MIDWIVES.
Disclosure UK Talking about Transparency.
Portfolio Committee on Police DNA National Forensics Oversight and Ethics Board 23 November 2016.
Medicines Control Council (MCC) &
ATHOC CODE OF PRACTICE and Ethics
Disclosure UK Talking about Transparency.
INDEPENDENT REGULATORY BOARD FOR AUDITORS
The Insurance Brokers Code of Practice - an update
The Economic Regulation of Transport Bill, 2018
Overview of the Office of Health Standards Compliance
OHSC 2018 CONSULTATIVE WORKSHOPS CERTIFICATION AND ENFORCEMENT
AGREEMENT FOR TRANSPARENCY The Case of Mexico
Registration Policy and Practice First Aid Forward
Medicines Control Council (MCC) &
Overview of the Office of Health Standards Compliance
Purpose & Overview of the Office of Health Standards Compliance
Overview of the Office of Health Standards Compliance
Overview of the Office of Health Standards Compliance
Portfolio Committee on Police DNA National Forensics Oversight and Ethics Board 23 November 2016.
Overview of the Office of Health Standards Compliance
Overview of the Office of Health Standards Compliance
Updates to the PhRMA Code on Interactions with Healthcare Professionals National Pharma Audioconference August 5, 2008.
Overview of the Office of Health Standards Compliance
Overview of the Office of Health Standards Compliance
Presentation transcript:

November 2010

 The Case for a Marketing Code of Practice  The Marketing Code of Practice Journey  The Parts to the Code  So What?  Examples & Scenarios  Current Challenges  Next Steps

SA Code of Practice for the Marketing of Health Products

 Ethical promotion of health products  To ensure that health care professionals and the public have access to the information they need  That patients have access to the health products they need  That health products are prescribed and used in a manner that provides the maximum healthcare benefit to patients  Promotional activities that comply with applicable legal, regulatory and professional requirements

 To enhance the rational use of health products and fair competition in the marketing thereof  To establish a clear understanding of the appropriate use of health products  Accurate information about health products is integral to providing quality healthcare services to patients  Preserve the independence of the decisions taken by healthcare professionals

SA Code of Practice for the Marketing of Health Products

July 2007 – Marketing Steering Committee 2009 – SAMED & SALDA join Feb 2010 – Interim Board of the MCA Oct 2010 – Agreed version of the Code and MoU Launch

 INNOVATIVE MEDICINES SA (IMSA)  NATIONAL ASSOCIATION OF PHARMACEUTICAL MANUFACTURERS (NAPM)  PHARMACEUTICALS MADE IN SA (PHARMISA)  PHARMACEUTICAL INDUSTRY ASSOCIATION OF SA (PIASA)  SELF-MEDICATION MANUFACTURERS ASSOCIATION OF SA (SMASA)  THE SOUTH AFRICAN ANIMAL HEALTH ASSOCIATION (SAAHA)  SOUTH AFRICAN MEDICAL DEVICE INDUSTRY ASSOCIATION (SAMED)  SOUTHERN AFRICAN LABORATORY DIAGNOSTICS ASSOCIATION (SALDA)  PHARMACEUTICAL WHOLESALERS AND DISTRIBUTORS  PHARMACEUTICAL SOCIETY OF SOUTHERN AFRICA (PSSA)

SA Code of Practice for the Marketing of Health Products

 PART A – Marketing and promotion of health products to healthcare professionals (19 clauses)  PART B – Marketing and promotion of health products directly to the consumer (18 clauses)  PART C – Medical Devices (7 clauses)  PART D – Provision for enforcement of the Code (12 clauses) The Code is further supported by Guidelines to the Interpretation of the Code and a Sanction & Corrective Action Proposal

SA Code of Practice for the Marketing of Health Products

 PART A – Marketing and promotion of health products to healthcare professionals

 PART B – Marketing and promotion of health products directly to the consumer

 PART C – Medical Devices

 PART D – Provision for enforcement of the Code SA Marketing

Breach Classification Expanded definitionCorrective Action/Public DisclosureFineTimelines MinorNo safety implications for patients’ well being No effect on how healthcare professionals will use product Immediate withdrawal of material/activity from market Company to Issue a corrective statement, as determined by MCA, including target audience Written reprimand to company by MCA Notify HCP of breach, if relevant R6K- R100K 30 days ModerateNo safety implications to patients’ wellbeing May have effect on how healthcare professionals will use product Immediate withdrawal of material/activity from market Company to Issue a corrective statement, as determined by MCA, including target audience Written reprimand to company by MCA Notify HCP of breach, if relevant Publication of corrective advertisement, as determined by MCA, including target audience R100K- R200K 30 days Serious/SevereWill have safety implications to patients’ wellbeing Will have effect on how healthcare professionals will use product Commercial impact on relevant market Activities that bring disrepute to industry or reduce confidence in the industry Immediate withdrawal of material/activity from market Written reprimand to company by MCA Publication of corrective advertisement, as determined by MCA, including target audience Issue a corrective letter to healthcare professionals/public, as determined by MCA R200K – R300K 30 days

Breach Classification Expanded definitionCorrective Action/Public DisclosureFineTimelines Fines not paidWhen a monetary fine is not paid within the required time period from receipt of the decisions and the reasons for the decisions of the MCA Further fine of R50K 60 days Corrective Action not implemented Where corrective action has not been actioned within required timelines Any other sanction including orders as to cost and fees The matter will be raised by MCA with the subject company and may be taken to MCA for consideration Further fine of R100K 60 days Repeated Breaches>3 infringements in 1 year When a company repeats any breach, as classified by MCA, in the promotion/activity of any of the company’s products/activity The MCA may publish the decision in a newspaper with national circulation along with the name of the offending company. Publication of the infraction on MCA website All postings will remain on website for 12 months. Inform the MCC of infringement and recommend cancellation of registration of product First:R10K + original fine; Second: R15K + original fine; Third: R25K + original fine R200K max MCC can cancel product registration 60 days

Breach ClassificationExpanded definitionCorrective Action/Public DisclosureFineTimelines Multiple breachesWhere the MCA, through monitoring, finds a number of breaches of the Code by a company: MCA will usually consider the aggregate of the breaches to determine whether a sanction should be imposed The MCA may publish the decision in a newspaper with national circulation along with the name of the offending company. Publication of the infraction on MCA website Inform the MCC of infringement and recommend cancellation of registration of product/s involved MCA may impose a sanction in respect of each breach of the Code, but may choose to impose an additional financial sanction MCC can cancel product registration 60 days Invalid / unjustified / vexatious complaints Does not comply with requirement of complaint as defined in Code MCA informs complainant in writing R10K 60 days Bringing the Code into disrepute When a company brings the Code into disrepute or misrepresents the Code The MCA may publish the decision in a newspaper with national circulation along with the name of the offending company. Publication of infraction on MCA website R200K max 60 days

SA Code of Practice for the Marketing of Health Products

 Finalise signatories to the Memorandum of Understanding to establish the Marketing Code Authority  Appoint an Executive Officer  Finalise Marketing Code Launch Plan  Launch the SA Code of Practice for the Marketing of Health Products  Fully-developed training programme  Public Relations Campaign SA Code of Practice for the Marketing of Health Products